To be or not to be B7
Open Access
- 2 October 2006
- journal article
- editorial
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 116 (10), 2590-2593
- https://doi.org/10.1172/JCI30103
Abstract
The activation of lymphocytes and development of adaptive immune responses is initiated by the engagement of TCRs by antigenic peptide–MHC complexes and shaped at the clonal level by both positive and negative costimulatory signals. The B7 family members are involved at several stages in this process. In this issue of the JCI, Vogt et al. show that the B7 family–related protein V-set and Ig domain–containing 4 (VSIG4) can act as an inhibitor of T cell activation (see the related article beginning on page 2817). Intriguingly, the same molecule was recently independently identified as a complement receptor of the Ig superfamily (CRIg) and was convincingly demonstrated to be a receptor for complement component 3 fragments. These findings raise interesting questions regarding the physiological roles and mechanisms of action of this molecule. Identification of dual functions of this molecule provides an additional level of complexity in T cell costimulation.Keywords
This publication has 16 references indexed in Scilit:
- VSIG4, a B7 family-related protein, is a negative regulator of T cell activationJCI Insight, 2006
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- The PD-1–PD-L pathway in immunological toleranceTrends in Immunology, 2006
- CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating PathogensCell, 2006
- The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytesMolecular Immunology, 2006
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapyCurrent Opinion in Immunology, 2006
- Restoring function in exhausted CD8 T cells during chronic viral infectionNature, 2005
- Characterization of monoclonal antibody specific to the Z39Ig protein, a member of immunoglobulin superfamilyImmunology Letters, 2005
- The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of functionImmunology Today, 1992
- Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.JCI Insight, 1988